Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022, issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS. Fred Hutch researchers Peter Gilbert, a research professor of biostatistics at the University of Washington School of Public Health, and Yunda Huang, a UW affiliate associate professor of global health, are the paper’s co-first authors.